Primary Glioblastoma with Different Patterns of EGFR Amplification and the Relationship with Gene Expression Profile

López‐Ginés, Concha; Gil-Benso, Rosario; Monleón, Daniel; González-Darder, José M.; Cerdá-Nicolás, Miguel

doi:10.5772/21697

Cited by 2 publications

(2 citation statements)

References 98 publications

(98 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gaitonde et al showed positive EGFR expression in 8 of 30 cases of astrocytoma [33]. Gines et al found that 53% of primary glioblastoma showed EGFR amplification and 33% of them showed EGFR over-expression [36]. Smith et al, showed that EGFR amplification was present in 17% of anaplastic astrocytoma and 41% of glioblastomas [20].…”

Section: Discussionmentioning

confidence: 99%

“…Gaitonde et al showed in their study that out of 30 cases with astrocytoma, 2 cases were of grade I-II, 11 cases were of the anaplastic type, 13 cases were of glioblastoma type and 4 cases were of other histological types [33]. This difference in grade frequency among different studies may suggest geographical or environmental causes as Iraqi studies show the predominance of grade II while worldwide studies reveal grade IV predominance EGFR amplification is rare in low-grade gliomas [32], [33], [34], [35], [36] however, many studies have reported EGFR amplification varying in ranges of 0-4%, 0-33% and 34%-64% in grade II, III and IV astrocytomas, respectively [17], [18], [19], [20], [21].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients

Abdulghani

Abbas

Mohammed

2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

BACKGROUND: Diffuse astrocytomas constitute the largest group of primary malignant human intracranial tumours. They are classified by the World Health Organization (WHO) into three histological malignancy grades: diffuse astrocytomas (grade II), anaplastic astrocytomas (grade III) and glioblastoma (grade IV) based on histopathological features such as cellular atypia, mitotic activity, necrosis and microvascular proliferation. Epidermal growth factor receptor (EGFR) is a 170-kDa transmembrane tyrosine kinase receptor expressed in a variety of normal and malignant cells regulating critical cellular processes. When activated, epidermal growth factor receptor (EGFR) triggers several signalling cascades leading to increased proliferation and angiogenesis and decreased apoptosis and hence associated with aggressive progression of the tumour. Epidermal growth factor receptor (EGFR) level is known to be a strong indicator associated with the aggressive behaviour of the tumour and acts as a prognostic factor for evaluating the survival rate. AIM: To evaluate the expression of epidermal growth factor receptor (EGFR) in different grades of astrocytoma. MATERIAL AND METHODS: formalin-fixed paraffin-embedded astrocytic tumours of 44 patients were collected from the archival material of pathology department of Ghazi Al Hariri Teaching Hospital during the period from June to December 2018. Hematoxylin and eosin-stained sections were used to characterise the tumours histologically based on cellularity, nuclear hyperchromasia, polymorphism, mitotic activity, vascular proliferation and necrosis with or without pseudopallisading of tumour cells. Diagnosis and grading of astrocytic tumours in this study were made according to WHO criteria (2016). Using a monoclonal antibody to the epidermal growth factor receptor (EGFR) and immunohistochemical analysis, the expression and distribution of epidermal growth factor receptor in astrocytic tumours were examined. RESULTS: The study included 1 case pilocytic astrocytoma (grade I), 20 cases diffuse astrocytoma (grade II), 5 cases anaplastic astrocytoma (grade III) and 18 cases of glioblastoma (grade IV). Expression of EGFR was found in 38.88% of the glioblastoma samples (grade IV). However, none of the astrocytomas of WHO grades I, II and III showed immunoreactivity for EGFR protein. Different patterns of immunoreactive cells and significant intratumor heterogeneity of EGFR expression were observed in glioblastomas. CONCLUSION: The immunohistochemical expression of Epidermal growth factor receptor (EGFR) was restricted only to high-grade astrocytic tumours, namely glioblastoma, thus may use to predict glioblastoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients

Abdulghani

Abbas

Mohammed

2019

Open Access Maced J Med Sci

View full text Add to dashboard Cite

show abstract

Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma

2015

View full text Add to dashboard Cite

BackgroundWith recent advancements in molecular techniques, the opportunities to gather whole genome information have increased, even in degraded samples such as FFPE tissues. As a result, a broader view of the genomic landscape of solid tumors may be explored. Whole genome copy number and loss of heterozygosity patterns can advance our understanding of mechanisms and complexity of various tumors.ResultsGenome-wide alterations involving copy number changes and loss of heterozygosity were identified in 17 glioma samples with positive FISH results for 1p19q co-deletions (n = 9) or EGFR amplification (n = 8). Gliomas positive for 1p19q co-deletions did not have other frequently recurrent genomic alterations. Additional copy-number alterations were observed in individual cases, and consisted primarily of large-scale changes, including gains or losses of entire chromosomes. The genomic architecture of EGFR amplified gliomas was much more complex, with a high number of gains and losses across the genome. Recurrent alterations in EGFR amplified gliomas were both focal, such as CDKN2A homozygous deletions, and large, such as chromosome 10 loss.ConclusionsMicroarray enabled a broader picture of the genomic alterations occurring in glioma cases. Gliomas with 1p19q co-deletion had a relatively quiet genome, apart from the selected co-deletion. Additional alterations in isolated cases, involved primarily larger aberrations. On the other hand, EGFR amplified cases tended to be more complex and have specific abnormalities associated with the EGFR amplification. Furthermore, 1p19q co-deletions and EGFR amplification associated copy number changes appeared to often be mutually exclusive.

show abstract

Primary Glioblastoma with Different Patterns of EGFR Amplification and the Relationship with Gene Expression Profile

Cited by 2 publications

References 98 publications

Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients

Immunohistochemical Expression of Epidermal Growth Factor Receptor in Astrocytic Tumors in Iraqi Patients

Observations of the genomic landscape beyond 1p19q deletions and EGFR amplification in glioma

Contact Info

Product

Resources

About